Oncimmune Holdings PLC (LON:ONC) chief executive Dr. Adam Hill speaks to Proactive London about their sixfold increase in revenue in the six months to the end of November.
Hill talks through the highlights of the period which saw a marked increase in commercial activity for its ImmunoSIGHTS services.
He puts this down to large pharmaceutical and leading biotech companies recognising the advantages of using Oncimmune's two proprietary biomarker discovery platform technology tools, SeroTag and NavigAID.
Half-year revenue rose to £1.83mln from £308,000 the year before.